Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran

  • Alireza Abdollahi Associate Professor of Pathology, Department of Pathology, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  • Mehrnoosh Etemadi Students of Scientific Research Centre, Tehran University of Medical Sciences, Tehran, Iran
Triple-negative breast cancer, Epidemiology, Iranian patients


Background: Triple-negative breast cancers (TNBC) are defined as breast cancers with lack of estrogen and progesterone receptors and no overexpression of human epidermal growth factor receptor 2 (HER2). This study was performed to determine the frequency and pathologic features of TNBC in Iranian patients.

Subjects and Methods: This cross-sectional study was performed on patients with breast cancer who referred to Cancer Institute, affiliated to Tehran University of Medical Sciences, from April 2014 to April 2015. Data about the demographics, the status of gene receptors and the pathologic features were extracted from patients’ records.

Results: Of 214 pathology samples of patients with malignant breast cancer, TNBCs account for 14% of cases. The mean age in N-TNBC group was 50 ± 12 years. Significant difference was seen between the age of two groups (p=0.03). No significant difference was observed regarding the number of involved lymph nodes between two groups (p=0.058). Presence of vascular and nerve invasion and involvement of surgical margins at the time of diagnosis were significantly more frequent in TNBC group comparing with N-TNBC. Grade III of histologic and nuclear grading was significantly more common in TNBC.

Conclusion: TNBC group was significantly associated with higher grade, higher mitotic indices and higher rate of P53 positivity and higher level of Ki-67 at the time of diagnosis. High grade breast cancers are more seen in TNBC. The presence of aforementioned characteristics in a patient highlights the need for evaluating TNBC biomarkers to better predict prognosis and consider appropriate treatment.


Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.

Muñoz M, Estévez LG, Alvarez I, et al. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treat Rev. 2008; 34(8):701-9.

Mousavi SM, Montazeri A, Mohagheghi MA, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007; 13(4):383-91.

Abd El‐Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004; 203(2):661-71.

Rubovszky G, Udvarhelyi N, Horváth Z, et al. Triple-negative breast carcinoma-rewiev of current literature. Magy onkol. 2010; 54(4):325-35.

Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer. 2007; 110(4):876-84.

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67.

Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34.

Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81.

Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer. Cancer. 2008; 113(10):2638-45.

Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011; 117(8):1602-11.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48.

De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 2010; 36 Suppl 3:S80-6.

Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 2010; 3:42.

Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34.

Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer. 2007; 109(9):1721-8.

Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24(36):5652-7.

Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7:134.

Rakha EA, El‐Sayed ME, Green AR, et al. Prognostic markers in triple‐negative breast cancer. Cancer. 2007; 109(1):25-32.

Suresh P, Batra U, Doval DC. Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. Indian J Med Paediatr Oncol. 2013; 34(2):89-95.

Amirikia KC, Mills P, Bush J, et al. Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women. Cancer. 2011; 117(12):2747-53.

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6:vi7-12.

How to Cite
Abdollahi A, Etemadi M. Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran. Int J Hematol Oncol Stem Cell Res. 10(4):200-205.